Navigation Links
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer
Date:9/29/2009

WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo-controlled Phase 2 trial sponsored by Northwestern University. The study, which evaluated Nexavar® (sorafenib) tablets in combination with the chemotherapeutic agent, paclitaxel, in patients with locally advanced or metastatic HER-2 negative breast cancer, demonstrated a positive trend towards improvement of progression-free survival in the treatment group (p-value=0.09). The safety and tolerability profile of the combination was consistent with the previous experience with each agent and no new toxicities were observed.

A complete data analysis from this study is expected to be presented at an upcoming scientific meeting. Patients are continuing to be followed for a secondary endpoint of overall survival.

The trial was led by principle investigator William Gradishar, M.D., professor of medicine, Robert H. Lurie Comprehensive Cancer Center of Northwestern University. "These encouraging data warrant further investigation to determine the potential of the Nexavar and paclitaxel treatment combination in patients with advanced breast cancer, an often underserved patient population," said Dr. Gradishar.

"The preliminary results in this study demonstrate a clinical signal in favor of this treatment combination. These data require further analysis and interpretation before we determine the appropriate path forward," said Todd Yancey, M.D., vice president of clinical development at Onyx. "This trial is the second of four from our comprehensive clinical program in breast cancer, which is intended to explore Nexavar's utility in a number of disease settings."

Bayer and Onyx recently reported statistically sig
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Docs Miss Test Results -- Even With Alerts
2. Results From Landmark PROSPECT Trial Demonstrate the Ability of Volcanos VH(R) IVUS Imaging to Identify Plaques Most Likely to Cause Heart Attacks
3. Video: New Clinical Trial Results Show Germ-Killing Action of LISTERINE(R) Antiseptic Kills Germs in the Mouth Before They Travel to the Bloodstream
4. Volcano Corporation Praises FAME Study Results
5. Dynatronics to Release Fourth Quarter and Year-end Results Friday, September 25, 2009; Conference Call Set for 12:30 p.m. ET
6. InVitria Presents Zap-CHO Performance Results at PEACe Conference
7. Natural Alternatives International, Inc. Announces Fiscal 2009 Q4 and Full Year Results
8. Assurant to Announce 2009 Third Quarter Results Oct. 28, 2009 and Host Webcast Conference Call Oct. 29
9. SpectraScience Announces Results of Annual Shareholder Meeting
10. One-year results from Horizons-AMI trial reported at TCT 2009
11. New type of sirolimus-eluting stent demonstrates superior results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014 College of Osteopathic Medicine of the ... the lobby of Western University of Health Sciences’ Patient Care ... Gomez about his medications, his blood pressure readings, and whether ... a lot. He’s a good man,” Gomez said. “He’s going ... patient are part of the Longitudinal Chronic Care Course (LC3), ...
(Date:9/15/2014)... The Best Hospitals Honor Roll ... seven hospitals using OnBase as their enterprise content ... were ranked at the top of the list, earning ... nearly 5,000 medical centers across the country with the ... highest in at least six of the sixteen specialties ...
(Date:9/15/2014)... New York, New York (PRWEB) September 15, 2014 ... against C.R. Bard, Inc. continue to move forward in ... Court, Southern District of West Virginia, Bernstein Liebhard LLP ... Court issued a Final Order on September 10th that ... litigation. The Order notes that none of the affected ...
(Date:9/15/2014)... (HealthDay News) -- U.S. heart experts recommend doctors use ... evaluating young people for underlying heart disease that could ... Association and the American College of Cardiology said in ... family medical history along with a physical examination can ... from birth) risks for sudden cardiac death. ...
(Date:9/15/2014)... A new, large cohort analysis from the prospective Prostate, ... that men who had moderate baldness affecting both the ... 45 were at a 40% increased risk of developing ... resulting in poorer prognosis relative to non-aggressive prostate cancer) ... There was no significant link between other patterns of ...
Breaking Medicine News(10 mins):Health News:COMP Takes the Long View of Health Care 2Health News:COMP Takes the Long View of Health Care 3Health News:COMP Takes the Long View of Health Care 4Health News:Seven of Top Ten Hospitals in the U.S. Leverage OnBase by Hyland ECM Solution 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 2Health News:Heart Docs Don't Recommend Routine ECGs for Young Athletes 3Health News:Certain form of baldness at age 45 linked to higher risk of aggressive prostate cancer 2
... to unpasteurized milk rising in the United States, a ... Clinical Infectious Diseases examines the dangers of ... cornerstones of a healthy diet. However, if those ... health hazard because of possible contamination with pathogenic bacteria. ...
... Speed , , BOSTON, Dec. 16 John Hancock ... website ( www.jhltc.com ) to make it easier for financial professionals to access and ... , Enhancements to the site include: , , ... Faster speed of processing , Improved design and ...
... they know. Or maybe not. A new study published in Human Molecular ... genome must pay attention to ancestry when analyzing and interpreting their results. ... ... where their ancestors were from and odds are that they know. Or ...
... To Wear Pink Founder Terry,Wheatley announced on Wednesday at ... that the grassroots cowboy campaign to fight breast,cancer has ... the,efforts of regional rodeos and western across the country. ... cancer charities and go to national,breast cancer research projects. ...
... ROME, Dec. 16 The United Nations World Food Program (WFP) ... needs a fraction of what is proposed for financial rescue packages ... "We need to send a bold signal of hope ... Executive Director of the World Food Program, speaking from New Delhi ...
... 16 Donor mother Kim Morsching will,be among 26 float ... here on New Year,s Day. This year,s theme, "The ... gift of life possible for others. Kim,Morsching,s real-life star, ... a tragic accident in 2007. , South Dakota ...
Cached Medicine News:Health News:Unpasteurized milk poses health risks without benefits 2Health News:John Hancock LTC Enhances Producer Website 2Health News:John Hancock LTC Enhances Producer Website 3Health News:Genome-wide Association Studies Must Account for Ancestry 2Health News:Genome-wide Association Studies Must Account for Ancestry 3Health News:The Western Community Shows Its Heart by Wearing Pink! 2Health News:WFP Calls for Rescue Package for the World's Hungry 2Health News:WFP Calls for Rescue Package for the World's Hungry 3Health News:WFP Calls for Rescue Package for the World's Hungry 4Health News:Young Athlete's Gift of Life to be Honored on Rose Parade Float 2
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... BRUSSELS , Sept. 15, 2014 Amgen ... today announced results from several exploratory analyses of the ... low bone mineral density (BMD). Romosozumab is an investigational ... the protein sclerostin, thereby increasing bone formation and decreasing ... Society for Bone and Mineral Research (ASBMR) 2014 Annual ...
(Date:9/15/2014)... 2014 myMatrixx has extended its contract with ... an expanded role that includes direct involvement in the ... nationally recognized physiatrist and pain management specialist, published author, ... workers, compensation, is Board Certified in physical medicine and ... Pain Medicine and subspecialty boarded by the American Board ...
Breaking Medicine Technology:Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 2New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 3New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 4New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 5New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 6New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 7New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 8New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 9New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 10New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 11New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 12New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 13New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 14New Analyses Of Phase 2 Study Presented At ASBMR Show Romosozumab Treatment Resulted In Continued Increases In Bone Mineral Density 15myMatrixx Announces Expanded Role for Medical Director Steven P. Stanos, Jr., DO 2
... Products provide the surgeon ... products for unparalleled fluid ... of fine microsurgical instruments. ... is highly absorbent, fast ...
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Hard protective shields for post-operative or post-injury use. Universal, or Left/Right specific. Packaged 12 per box....
Medicine Products: